In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells

Blood

Volumn 120, Issue 24, 2012, Pages 4846-4849

  Soucie, Erinn ^a   Hanssens, Katia ^a   Mercher, Thomas ^b   Georgin Lavialle, Sophie ^c,d,e   Damaj, Gandhi ^f   Livideanu, Cristina ^g   Chandesris, Maria Olivia ^c   Acin, Yolène ^h   Létard, Sebastien ^a   De Sepulveda, Paulo ^a   Hermine, Olivier ^c,d   Bernard, Olivier A ^b   Dubreuil, Patrice ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d CNRS   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

^g SERVICE DE PNEUMOLOGIE   (France)

^h AB Science   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; CHRONIC MYELOMONOCYTIC LEUKEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAST CELL; MASTOCYTOSIS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE C KIT; PRIORITY JOURNAL; TET2 GENE; TUMOR SUPPRESSOR GENE;

EID: 84870766228     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-397588     Document Type: Article

References (20)

1. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2011;157(3):215-225.
2. Casteran N, De Sepulveda P, Beslu N, et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene. 2003;22(30):4710-4722. (Pubitemid 36976446)
3. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the protooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993;92(4):1736-1744. (Pubitemid 23304537)
4. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7):2366-2372. (Pubitemid 44497521)
5. Mayerhofer M, Gleixner KV, Hoelbl A, et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol. 2008;180(8):5466-5476.
6. Zappulla JP, Dubreuil P, Desbois S, et al. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med. 2005;202(12):1635-1641. (Pubitemid 41815869)
7. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(2):603-625. (Pubitemid 32506768)
8. Ferrao PT, Gonda TJ, Ashman LK. Constitutively active mutant D816VKit induces megakaryocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. Leuk Res. 2003;27(6):547-555. (Pubitemid 36315787)
9. Mohr F, Döhner K, Buske C, Rawat VP. TET genes: new players in DNA demethylation and important determinants for stemness. Exp Hematol. 2011;39(3):272-281.
10. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466(7310):1129-1133.
11. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839-843.
12. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
13. Langemeijer SM, Jansen JH, Hooijer J, et al. TET2 mutations in childhood leukemia. Leukemia. 2011;25(1):189-192.
14. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009;23(7):1343-1345.
15. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23(5):900-904.
16. Bodemer C, Hermine O, Palmérini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3):804-815.
17. Yang Y, Létard S, Borge L, et al. Pediatric mastocytosis- associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood. 2010;116(7):1114-1123.
18. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144-147.
19. Quivoron C, Couronné L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25-38.
20. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell selfrenewal and myeloid transformation. Cancer Cell. 2011;20(1):11-24.